Valeant Pharmaceuticals International, Inc. Sustainability Profile
Valeant Pharmaceuticals International, Inc., commonly referred to as Valeant, is a prominent player in the global pharmaceutical industry, headquartered in the United States. Founded in 1960, the company has established a significant presence in various operational regions, including North America, Europe, and Asia. Valeant focuses on specialty pharmaceuticals and over-the-counter products, with a diverse portfolio that includes dermatology, ophthalmology, and neurology. The company is known for its innovative approach to drug development and its commitment to addressing unmet medical needs. Valeant's unique offerings, such as its advanced dermatological treatments and specialty pharmaceuticals, have positioned it as a leader in the market. With a history of strategic acquisitions and a robust pipeline, Valeant continues to achieve notable milestones, solidifying its reputation as a key player in the pharmaceutical landscape.
DitchCarbon Score
How does Valeant Pharmaceuticals International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Valeant Pharmaceuticals International, Inc.'s score of 20 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Valeant Pharmaceuticals International, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Bausch Health Companies Inc., which means that any emissions data or climate commitments would be inherited from this parent organisation. Bausch Health Companies Inc. has not publicly disclosed specific reduction targets or initiatives related to carbon emissions, nor have they committed to any climate pledges. As a result, Valeant Pharmaceuticals does not have defined emissions reduction strategies or targets at this time. Given the lack of specific emissions data and reduction initiatives, it is important to note that the pharmaceutical industry is increasingly focusing on sustainability and climate commitments. Companies are encouraged to adopt science-based targets and participate in initiatives such as the Science Based Targets initiative (SBTi) to align with global climate goals. In summary, Valeant Pharmaceuticals International, Inc. currently lacks detailed emissions data and specific climate commitments, relying on the broader sustainability framework established by its parent company, Bausch Health Companies Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Valeant Pharmaceuticals International, Inc.'s Industry?
How Carbon Intensive is Valeant Pharmaceuticals International, Inc.'s Location?
Valeant Pharmaceuticals International, Inc.'s Scope 3 Categories Breakdown
Valeant Pharmaceuticals International, Inc.'s Scope 3 emissions, which increased by 41% last year and increased by approximately 41% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 21% of total emissions under the GHG Protocol, with "Waste Generated in Operations" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Valeant Pharmaceuticals International, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Valeant Pharmaceuticals International, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Compare Valeant Pharmaceuticals International, Inc.'s Emissions with Industry Peers
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.